{"name":"Jaeb Center for Health Research","slug":"jaeb-center-for-health-research","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Triamcinolone Acetonide + laser","genericName":"Triamcinolone Acetonide + laser","slug":"triamcinolone-acetonide-laser","indication":"Diabetic macular edema","status":"phase_3"},{"name":"Deferred aflibercept","genericName":"Deferred aflibercept","slug":"deferred-aflibercept","indication":"Diabetic macular edema (DME)","status":"phase_3"},{"name":"Ranibizumab + laser","genericName":"Ranibizumab + laser","slug":"ranibizumab-laser","indication":"Proliferative diabetic retinopathy (PDR)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Bevacizumab + Deferred Aflibercept Group","genericName":"Bevacizumab + Deferred Aflibercept Group","slug":"bevacizumab-deferred-aflibercept-group","indication":"Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational)","status":"phase_3"},{"name":"Prompt aflibercept","genericName":"Prompt aflibercept","slug":"prompt-aflibercept","indication":"Diabetic macular edema (DME)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Placebo Eyedrops","genericName":"Placebo Eyedrops","slug":"placebo-eyedrops","indication":"Control comparator in ophthalmic clinical trials (specific indication depends on concurrent active treatment arm)","status":"phase_3"},{"name":"Ranibizumab + deferred laser","genericName":"Ranibizumab + deferred laser","slug":"ranibizumab-deferred-laser","indication":"Treatment of neovascular (wet) age-related macular degeneration","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Sham injection + laser","genericName":"Sham injection + laser","slug":"sham-injection-laser","indication":"Treatment of psoriasis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"intravitreous aflibercept","genericName":"intravitreous aflibercept","slug":"intravitreous-aflibercept","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Triamcinolone Acetonide + laser","genericName":"Triamcinolone Acetonide + laser","slug":"triamcinolone-acetonide-laser","phase":"phase_3","mechanism":"Triamcinolone acetonide is a corticosteroid that reduces inflammation, combined with laser treatment to mechanically ablate or coagulate tissue, used together to treat retinal conditions.","indications":["Diabetic macular edema","Retinal vein occlusion with macular edema"],"catalyst":""},{"name":"Bevacizumab + Deferred Aflibercept Group","genericName":"Bevacizumab + Deferred Aflibercept Group","slug":"bevacizumab-deferred-aflibercept-group","phase":"phase_3","mechanism":"This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation.","indications":["Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational)","Potentially other solid tumors with VEGF-dependent angiogenesis"],"catalyst":""},{"name":"Deferred aflibercept","genericName":"Deferred aflibercept","slug":"deferred-aflibercept","phase":"phase_3","mechanism":"Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors.","indications":["Diabetic macular edema (DME)","Retinal vein occlusion (RVO)","Age-related macular degeneration (AMD)"],"catalyst":""},{"name":"Placebo Eyedrops","genericName":"Placebo Eyedrops","slug":"placebo-eyedrops","phase":"phase_3","mechanism":"Placebo eyedrops contain no active pharmaceutical ingredient and produce therapeutic effects through the placebo effect.","indications":["Control comparator in ophthalmic clinical trials (specific indication depends on concurrent active treatment arm)"],"catalyst":""},{"name":"Prompt aflibercept","genericName":"Prompt aflibercept","slug":"prompt-aflibercept","phase":"phase_3","mechanism":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis.","indications":["Diabetic macular edema (DME)","Retinal vein occlusion (RVO)","Wet age-related macular degeneration (AMD)","Metastatic colorectal cancer (in combination with chemotherapy)"],"catalyst":""},{"name":"Ranibizumab + deferred laser","genericName":"Ranibizumab + deferred laser","slug":"ranibizumab-deferred-laser","phase":"phase_3","mechanism":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor.","indications":["Treatment of neovascular (wet) age-related macular degeneration","Treatment of macular edema following retinal vein occlusion"],"catalyst":""},{"name":"Ranibizumab + laser","genericName":"Ranibizumab + laser","slug":"ranibizumab-laser","phase":"phase_3","mechanism":"Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, combined with laser photocoagulation to seal leaking vessels in the retina.","indications":["Proliferative diabetic retinopathy (PDR)","Diabetic macular edema (DME) with retinal thickening"],"catalyst":""},{"name":"Sham injection + laser","genericName":"Sham injection + laser","slug":"sham-injection-laser","phase":"phase_3","mechanism":"This drug combines a sham injection with laser therapy, which is a non-pharmacological treatment approach.","indications":["Treatment of psoriasis"],"catalyst":""},{"name":"intravitreous aflibercept","genericName":"intravitreous aflibercept","slug":"intravitreous-aflibercept","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZ1FuSUdkS0o1ODBYMjMwdXBzbC1yLVJQb1lTQzFmalFobDA2b1AwcGw2dXA4QmpHc2wxbmhlMXhSclVLckk5djd5Q1UtV0NFaEFYemNyd0hacGZtcXpqQVRLS0dIbW5uVmJwNXdVcmxJc3RLeVhKQlU5eWVscm5qYmxLcThQY2stY3pBZG5qR0ctUlZoeEdyVktDVm53dDl5TW1vLWFaVDdNZ3pvUmRWU1JLRU1RWHRXd3Y4?oc=5","date":"2026-03-05","type":"pipeline","source":"Healio","summary":"HbA1c rose at 1 year in children with diabetes using inhaled insulin - Healio","headline":"HbA1c rose at 1 year in children with diabetes using inhaled insulin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQMk9fTG0wcG5KSUxpU2FtVDA0a0tIV01CM0VIRjhfSDN1dXNzODFfY3NBamE1WVhvdzF3QXByNGxSQ2E3N1ZtR28wQkU1elpyWUlySU02RUxJQ0JuOVZDVjdxcmplcXRfYjFmTmlUeWtIdDl3LUo2NHlwNS1hNUJQQnNEUnJVdE5nMkVYUEliM3BiWGdwYlVhWXZn?oc=5","date":"2025-06-04","type":"trial","source":"Drug Delivery Business","summary":"Researchers look to study AID in pregnant women with diabetes - Drug Delivery Business","headline":"Researchers look to study AID in pregnant women with diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE8tWlZTY3ZmVGFpOUI0bDRHNXlpRGw1TkM3UGtjZDlyRGlhLXpmOFptRVNuQUUzVEE2LUNqVkhCOFBEMjZsUTF1RFBob1hjVVd6NVM0aTk4UG1fYTQ1RnlRRlVMcVhsMDBnejllT3ZqWkJicFJkN0hhVkh3?oc=5","date":"2023-07-13","type":"pipeline","source":"MedPage Today","summary":"Low-Dose Atropine Eye Drops Flop for Slowing Kids' Myopia - MedPage Today","headline":"Low-Dose Atropine Eye Drops Flop for Slowing Kids' Myopia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5aOGs5S1ZuUUE3RzR0dVJScXhURDJHQkN6R254ZnNGaGJoNC12UE1qOC0zUURySXJINlUxOE5kMVdZdTd5OU1MWERPYUNaSVdPZWJOeDFjMlZsUjRQWEc1d2FDWUs0aTFCUGNjVHhHLU5KSTZBOExqME53?oc=5","date":"2023-02-07","type":"pipeline","source":"MedPage Today","summary":"No Visual Acuity Benefit With Early Anti-VEGF for Diabetic Retinopathy - MedPage Today","headline":"No Visual Acuity Benefit With Early Anti-VEGF for Diabetic Retinopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQWXk5VGNfTzZJUHpBRTVJeGt5TEhMMmFURnNyRUQxODlHV0dqN1lGSEoyVWpfQzR5cTFUbXhHRTcyQzBpZldJUVRLT2d2WHVGNk03OWtsSTFuTUpLT2hCRUk4WTV6V3FBa2tiQmdQZTNmX3cySjVhWllZaW1PRFUtdnV3bm82d0xBdVVPSQ?oc=5","date":"2023-01-25","type":"regulatory","source":"pharmaphorum","summary":"Automated insulin dosing app Tidepool Loop FDA-cleared - pharmaphorum","headline":"Automated insulin dosing app Tidepool Loop FDA-cleared","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5zZkxiVEhzeVJrRXFwSnI4bUdENHNUM0lrcnI3bEdzMnNoVzRLTlFxQnFlNXIzc0YzS2hweGg1Z0dMajBRa0ZyY3llZERLYmpJZDNSZWo2elpIcGh0WDBwb3RZcWhVWVp3OThqVDlR?oc=5","date":"2022-07-15","type":"pipeline","source":"time.com","summary":"The Latest Advancements in Type 2 Diabetes Care - time.com","headline":"The Latest Advancements in Type 2 Diabetes Care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQTWN4dVVTa0hvTlZSY2xZeko3a180TmJoR1lBUmNicnRFVlQzYnRPZ0gwRFBhWmRyRkJnejdPdmZlZkR6eW5jM1JTZklFbW1zaUpsVXNwRW16alMyUjFPbFlBQ1pGZEdyZFZOV2ZWdXZMSTNFQXRiZi0zemJlV1Y4ZjRRYw?oc=5","date":"2020-05-31","type":"pipeline","source":"American Academy of Ophthalmology","summary":"DRCR.net Five-Year Outcomes for Protocol T - American Academy of Ophthalmology","headline":"DRCR.net Five-Year Outcomes for Protocol T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9aYzFydXJyYlhwS05hZTJST0puVVQ5aGZDM2EtVTZkN2tCM1lVenZHeW1hSDJUZU1VaVR4YlplUXpNaWVWckFLQUxBU19HNDFXam93aGplbW9zYU4y?oc=5","date":"2020-03-24","type":"pipeline","source":"Beyond Type 1","summary":"Anti-VEGF Treatment for Prevention of PDR/DME - Beyond Type 1","headline":"Anti-VEGF Treatment for Prevention of PDR/DME - Beyond Type 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNYUo2eHE4REl3blpXNVJ3ZlNFZElSNDJ3MHFNQ0ozTG1ENFhGS3RETWdUZ29zMzBLQl9PUWdzQzc0RFJQeVZ4b3FGeHVwQ3FzRFFuY244M1JNemllanhOTXRyNWgza21OSTU2UGRMTXBBTkgzeWl6S2czZWNhQUxrOWhTWHd4RmxsYTlYcm9R?oc=5","date":"2018-02-19","type":"pipeline","source":"pharmaphorum","summary":"Tandem's insulin pump can predict and prevent hypo's - pharmaphorum","headline":"Tandem's insulin pump can predict and prevent hypo's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1KcVd0VTkyQzUyZFZITzVaT3g2ZkdkNTh0Mi1wak00bkRlbjV4TFJWcTNxN2tmNC1UZnA0aW5yREtEcjBjTmV5ZzJMYTg0U3lrRTBKeGhQRENCSTdwWjBqRTIwckZ0ZjJBRGVtU0hyRjR3dw?oc=5","date":"2017-08-23","type":"pipeline","source":"Medical Xpress","summary":"In T2D, glycemic control up with continuous glucose monitoring - Medical Xpress","headline":"In T2D, glycemic control up with continuous glucose monitoring","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_3":8,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}